Therapy Access Intelligence for brand teams
Confidence in decisions for launch & brand planning.
How can your product be used sustainably in day-to-day clinical practice?
IBEXX provides you with quantified insights from real clinical
practice. For Marketing, Medical & Access.
Identify your Barriers & Drivers in 3 weeks.
Quantification from day-to-day clinical practice in under 90 days.
Support with implementing the measures.
Current developments
01 Outpatient flat rates Switzerland
In Switzerland, since 2026, around 13% of outpatient cost volume has been billed via the new outpatient flat rates. This share is expected to rise to 34% in the coming years, nearly tripling. As a result, cost-efficient therapies are becoming significantly more important, as providers increasingly benefit within a flat rate from using available resources efficiently.
Source: https://www.bag.admin.ch/de/ambulanter-arzttarif?utm_source=chatgpt.com
02 Nasal ketamine
Approved does not mean ready for use. Ketamine therapy shows what launches really hinge on.
Treating depression with nasal ketamine requires trained staff for monitoring as well as suitable facilities, which must be available during the roughly two-hour treatment. Were these requirements sufficiently considered at launch?
Source: Tages-Anzeiger, August 5, 2026
03 Nursing staff competition Germany
Nursing time is becoming the scarcest resource in the market. Therapies that save it are welcomed.
In Germany, more than 350,000 foreign nursing professionals are employed. At the same time, international competition for qualified nursing staff is intensifying, and Germany is increasingly struggling to retain professionals long term.
This makes nursing time a scarce resource: therapies that reduce nursing workload can offer providers a decisive advantage.
Source: Handelsblatt, August 7, 2026
04 Nursing workforce forecast 2049
100,000 additional nursing professionals by 2049. Your therapy’s nursing workload also determines its use.
Hospitals in Germany are expected to need around 100,000 additional nursing professionals by 2049, an increase of 14%.
Against this backdrop, a therapy’s nursing requirements are increasingly becoming a relevant factor: Have you considered how your therapy affects nursing workload?
Source: Federal Statistical Office of Germany
05 Private physicians Austria
In Austria, there are now significantly more private physicians than statutory health insurance physicians. Most recently, there were 11,939 private physicians compared with 7,239 statutory health insurance physicians.
This increases the importance of a care segment that differs from the traditional statutory sector in financing, practice organization, and patient structure. Have you considered how this shift affects access to your therapy and its use in day-to-day care?
Source: MedMedia / RELATUS MED, July 30, 2026
The problem that is overlooked far too often
Do you recognize this?
Conducted studies, held advisory boards, completed the Launch Readiness Board—and still, after launch, barriers emerge that nobody knew about.
The KOL nods. The field force pushes. And the product still is not used.
In day-to-day clinical practice, the product requires staff or processes that simply do not exist.
“ As long as the black box of clinical practice remains opaque, every launch is a gamble. No matter how good your clinical data is.“
With Therapy Access Intelligence from IBEXX
This is what it can look like instead
You know before launch whether your product will be welcomed. (After 3 weeks)
You know what really determines uptake in day-to-day clinical practice.
You know in hours and costs what your therapy demands from the hospital.
The solution
You know the Launch Readiness Dashboard. IBEXX provides what is still missing from it.
IBEXX adds the one check to your brand plan that no standard method has provided so far: quantified care reality directly with providers. Not questionnaires. Not estimates. But process data from day-to-day clinical practice, made measurable before you launch.
What you get
Quantified Barriers & Drivers from real clinical practice—not assumptions.
Clarity on whether your product will be welcomed by providers.
A shared data foundation for Marketing, Medical & Access. One language, one meeting.
Results in under 90 days.
Two products
Each delivers a standalone outcome you can work with immediately.
Therapy Access Screening |
In 3 weeks
IBEXX adds the one check to your brand plan that no standard method has provided so far: quantified care reality directly with providers. Not questionnaires. Not estimates. But process data from day-to-day clinical practice, made measurable before you launch.
learn more ›
Therapy Access Quantification |
In 3 months
We validate and quantify the hypotheses in real day-to-day clinical practice. Assumptions become facts: hours, costs, processes, so you can incorporate the challenges of clinical practice into strategy and positioning.
And if you want to go further: We support you in validating and scaling your Therapy Access measures nationally and internationally.
“ The analysis of your Therapy Access Barriers & Drivers belongs in every launch plan. Like market analysis. Like the patient journey.“
For you in the brand team who want the same thing and have too rarely received it so far.
For Marketing, Medical & Access.
The brand team
A strong brand team is created when Marketing, Medical, and Access do not work alongside one another, but understand the same reality. IBEXX connects each function’s perspective into a shared view of what truly drives decisions in the market: where adoption happens, where it is blocked, and which priorities the team must set together. This creates a strategy that is more closely aligned with the reality of patients, care teams, and providersand therefore delivers greater impact in the market.
For brand
managers
If your product is not performing, it is not enough to communicate even louder. You need to know what is truly blocking success in day-to-day clinical practice: resources, processes, capacity, or economic barriers. IBEXX gives you this clarity so you can sharpen your brand story, set the right priorities, and strengthen your product where market share is actually won or lost.
For Medical
Advisors
Physicians can tell whether you are only talking about your product or whether you genuinely want to understand what it means for their hospital. IBEXX gives you the data and questions to have exactly that dialogue: fact-based, collaborative, and on equal footing. This strengthens your role as a subject-matter authority and makes you a relevant counterpart for KOLs, not just a source of information.
For Market Access Managers
What this means for you as a brand team
A strong brand team is created when Marketing, Medical, and Access do not work alongside one another, but understand the same reality. IBEXX connects each function’s perspective into a shared view of what truly drives decisions in the market: where adoption happens, where it is blocked, and which priorities the team must set together. This creates a strategy that is more closely aligned with the reality of patients, care teams, and providers—and therefore delivers greater impact in the market.
About us
We have been in your situation ourselves. That is why we built IBEXX.
We come from Pharma, Market Access, Commercial, and strategy consulting. We have supported launches ourselves where the product was good and still failed due to the real-world care reality, because nobody knew what the product truly meant in day-to-day clinical practice. We wanted to change that. Not with large consulting machines and 12-month projects, but with a dedicated discipline that quickly delivers what brand teams really need: quantified clarity. We call it Therapy Access Intelligence.
Insiders, not theorists.
We know day-to-day clinical practice: staff shortages, budget pressure, process hurdles. We see barriers before they derail your launch.
Quantification, not guesswork.
Advisory boards capture opinions. We measure what actually happens in the treatment center. Our methodology translates clinical practice into the language of the brand team, scientifically grounded and published.
Weeks, not months.
Our software enables analyses in a fraction of the time required by traditional consultancies. And with suitable contract structures, you avoid months of compliance loops.
The founders
Björn Grob, MSc
He experienced how a promising oncology launch failed due to the hospital’s cost barrier. Today, he ensures that brand teams know such barriers in advance.
Reto Marending, MSc
Across numerous product launches, he has seen that launch success depends not only on clinical data, but on whether a therapy is actually adopted and used in day-to-day clinical practice.
Dr. Wolfgang Tüchler
Our motivation
“ Innovative therapies should be available to as many patients as possible because critical barriers in clinical practice have been identified early.“
Offering
Two offerings to clarify your Barriers & Drivers in Therapy Access. Both work independently.
IBEXX adds the one check to your brand plan that no standard method has provided so far: quantified care reality directly with providers. Not questionnaires. Not estimates. But process data from day-to-day clinical practice, made measurable before you launch.
Therapy Access Screening
In 3 weeks
from €9,990/CHF
The fast reality check for your product.
Product Snapshot
Assessment across the 6 dimensions
Clear hypotheses on your Barriers & Drivers
Ideal before the brand plan or advisory board
Therapy Access Quantification
In 3 months
Price: on request
Robust numbers from real clinical practice.
Validation and quantification of your therapy processes
We analyze staff hours, infrastructure requirements, and material costs
Board-ready for Marketing, Medical & Access.
In under 90 days
Do you want to validate and scale your measures nationally and internationally? Ask us about Validation & Scale-Up.
Noch nicht überzeugt? Ein schneller Self-Check für Brand-Teams:
The Launch Readiness Check
for Brand Teams.
Questions you need to ask yourselves before launch—and that aren’t in any standard board deck. What will your product really face with providers? Which Barriers can you still address before launch? Where are doors open—and where not?
Let’s talk
You want to know whether your product will be welcomed.
We will show you.
No pitch. No presentation you have seen before. Just an honest, no-obligation 30-minute conversation about what your launch needs. You bring your product; we bring the view from day-to-day healthcare practice.
Initial hypotheses in the conversation.
Full screening in 3 weeks.
Quantified results in under 90 days.
